ANI Pharmaceuticals

In two facilities with combined manufacturing, packaging and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder and oral solid dose products, including those requiring containment. The Company also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. The fully-cGMP qualified facilities boast state-of-the-art analytical and stability laboratories for its rapidly expanding research and development program. 
Company Growth (employees)
Type
Public
HQ
Baudette, US
Founded
1996
Size (employees)
143 (est)
ANI Pharmaceuticals was founded in 1996 and is headquartered in Baudette, US

ANI Pharmaceuticals Office Locations

ANI Pharmaceuticals has an office in Baudette
Baudette, US (HQ)
210 Main St W
Baudette, US
455 Idc Rd SW

ANI Pharmaceuticals Financials and Metrics

ANI Pharmaceuticals Financials

ANI Pharmaceuticals's revenue was reported to be $128.6 m in FY, 2016
USD

Revenue (Q3, 2017)

48.2 m

Gross profit (Q3, 2017)

27.1 m

Gross profit margin (Q3, 2017), %

56%

Net income (Q3, 2017)

4.7 m

EBIT (Q3, 2017)

9.3 m

Market capitalization (13-Nov-2017)

722 m

Cash (30-Sep-2017)

18 m
ANI Pharmaceuticals's current market capitalization is $722 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

30.1 m56 m76.3 m128.6 m

Revenue growth, %

86%36%69%

Cost of goods sold

10 m11.5 m12.7 m48.8 m

Gross profit

20.1 m44.5 m63.6 m79.8 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

7.8 m10.9 m6.6 m17.4 m18.8 m19.5 m20 m20.6 m31.3 m38.5 m36.6 m44.8 m48.2 m

Cost of goods sold

2.6 m2.6 m2.1 m3.1 m2.8 m3.1 m3.3 m3.4 m11.8 m16.7 m16.4 m21.1 m21.1 m

Gross profit

5.2 m8.3 m4.5 m14.3 m16 m16.4 m16.7 m17.1 m19.5 m21.9 m20.2 m23.6 m27.1 m

Gross profit Margin, %

66%76%68%82%85%84%84%83%62%57%55%53%56%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

11.1 m169 m154.7 m27.4 m

Accounts Receivable

12.5 m17.3 m21.9 m45.9 m

Inventories

580 k1.1 m1.5 m26.2 m

Current Assets

27.7 m203.5 m192.6 m103 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

10.9 m53 m35.1 m165.6 m166.7 m150.9 m77.7 m15 m16.2 m10.8 m8.4 m18 m

Accounts Receivable

9.5 m

Inventories

2.8 m5.9 m7.3 m10.7 m12.7 m13.7 m13.9 m25.1 m28.3 m45.9 m42.3 m38.5 m

Current Assets

26.1 m67.2 m57.6 m203 m208.9 m197.5 m116.6 m79.8 m95.5 m107 m112.9 m125.6 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

301 k28.7 m15.4 m3.9 m

Depreciation and Amortization

1.1 m3.9 m6.9 m22.3 m

Accounts Receivable

(7.1 m)(4.8 m)(4.6 m)(24 m)

Inventories

(708 k)(3.5 m)(314 k)(647 k)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

3.4 m6.7 m4.4 m3.6 m4.6 m1.3 m1.1 m2.5 m1.2 m

Depreciation and Amortization

381.7 k703 k706 k1.2 m1.3 m1.4 m2 m4.6 m6 m6 m6.7 m

Accounts Payable

1.7 m3.1 m2.3 m1.3 m2.6 m3 m5 m4.7 m4.8 m
Y, 2017

Financial Leverage

2 x
Show all financial metrics

ANI Pharmaceuticals Market Value History

ANI Pharmaceuticals's Web-traffic and Trends

ANI Pharmaceuticals Company Life and Culture

You may also be interested in